Should you sell PACS Group, Inc. or reduce the position?
Calculate what you would remove, what you would retain, and which assumptions support continuing to own it.
Price as of Oct 18, 2026, 4:30 PM UTC (polygon last daily bar) · Evidence through Sep 9, 2026
What has changed in the case for owning it?
Market Ontology's model values PACS Group, Inc. at $56.94 per share against $46.91 (+21.4%). 8 dated developments in the last 45 days reach the position.
| Development | Evidence | Assumption affected | Consequence for the case |
|---|---|---|---|
| Sep 9, 2026 · PACS Group to Acquire 32 Florida Facilities with 4,049 Beds | 1 source | inorganic revenue growth via 32-facility operational expansion | Supports the case for owning |
| Sep 9, 2026 · PACS Group to Acquire 32 Skilled Nursing Facilities From Omega Healthcare in Florida | 1 source | operating bed capacity expansion lifting post-acute service revenues | Supports the case for owning |
| Sep 9, 2026 · PACS Group Agrees to Acquire 32 Skilled Nursing Facilities From Omega Healthcare | 1 source | operating bed capacity expansion | Supports the case for owning |
| Sep 9, 2026 · PACS Group to Acquire Operations of 32 Skilled Nursing Facilities in Florida | 1 source | revenue capacity growth via acquired facility bed count | Supports the case for owning |
| Sep 9, 2026 · PACS Group to Acquire 32 Florida Skilled Nursing Facilities from Omega Healthcare | 1 source | operating bed capacity expansion lifting regional post-acute market share | Supports the case for owning |
What changes if you sell?
| Keep current position | Sell selected quantity | Exit position | |
|---|---|---|---|
| Shares remaining | 100 | 50 | 0 |
| Estimated proceeds after included transaction costs | — | $2,344 | $4,689 |
| Downside case ($38.87) outcome | −$804 | −$402 | $0 |
| Upside case ($87.20) outcome | $4,029 | $2,015 | $0 |
| Remaining exposure | $4,691 | $2,346 | $0 |
Included costs: an assumed 5 bps for commission and spread. Tax treatment: not calculated; cost basis is not used in this comparison.
Undecided: sale proceeds and remaining exposure are calculated; replacement performance is left unresolved.
What would justify keeping the remaining position?
- Revenue growth (yr 1) holds near -1.29%: Trailing 4-year revenue CAGR of -1.3%, faded toward terminal growth over 5 years.
- Operating margin (steady-state) holds near 4.03%: Anchored to mean operating margin of 4.0% across the last 4 reported periods.
- Discount rate (WACC) holds near 6.51%: CAPM baseline: 5.10% risk-free + β0.26 × 5.5% ERP = 6.51%.
What would justify investigating it again after an exit?
- Implied revenue growth (next yr → terminal) moves relative to -8.33%: Growth rate that reconciles the current share price to a 5y DCF holding margin, WACC and terminal g fixed.
- Implied steady-state FCF margin moves relative to 7.88%: FCF margin the market needs to justify the current price at modeled growth and WACC.
- The price falls below the downside value of $38.87.
Preserve the reasoning behind the sale.
Save the reduction you're considering, the evidence behind it, and your conditions for reviewing the remaining position. If you exit, keep the research and specify what would justify revisiting PACS.
Should I buy?Should I hold?Should I hedge?How to hedgeImpact ledger